Roche Holding Ltd · SIX:RO
Roche — YTD Sep 2025 Earnings Presentation
166 slides from Roche's earnings presentation, Oct 23, 2025
Slide 1: Roche
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Roche YTD September 2025 sales
Roche YTD September 2025 sales Basel, 23 October 2025
Slide 4: Group
Group Thomas Schinecker Chief Executive Officer
Slide 5: YTD Sep 2025 Performance, Pipeline Update, Outlook
YTD Sep 2025 Performance Pipeline Update Outlook
Slide 6: YTD Sep 2025: Continued strong financial performance
YTD Sep 2025: Continued strong financial performance YTD September results at CER ▪ Group sales growth +7%, +9% for Pharma and +1% for Diagnostics (due to China healthcare pricing reforms) ▪ Full year LOE impact expectation lowered to CHF 0.8bn Key milestones achieved in Q3 ▪ Pharma regulatory: US a
Slide 7: YTD Sep 2025: Strong Pharma sales driving Group growth
YTD Sep 2025: Strong Pharma sales driving Group growth Diagnostics division growing +1% impacted by healthcare pricing reforms in China YTD Sep YTD Sep 2025 2024 Change in % CHFbn CHFbn CHF CER Pharmaceuticals Division 35.6 34.3 4 9 Diagnostics Division 10.3 10.7 -4 1 Roche Group 45.9 45.0 2 7 CER:
Slide 8: YTD Sep 2025: Consistent strong growth
YTD Sep 2025: Consistent strong growth Diagnostics impacted by healthcare pricing reforms in China Group sales growth %CER +15% +10% +9% +9% +9% +9% +8% +6% +6% +5% +2% +1% +2% +1% 0% COVID-19 pandemic Pandemic phase out Post-pandemic Base business: +1%* Base business: +8%* Business growth: +8%* 202
Slide 9: Key growth drivers of the Roche portfolio
Key growth drivers of the Roche portfolio All therapeutic areas delivering strong growth; Diagnostics impacted by healthcare pricing reforms in China Diagnostics: Molecular Lab and YTD Sep 2025 sales Pathology Lab with strong growth; Core (CHFbn, YoY CER growth) Lab impacted by China healthcare +1%
Slide 10: YTD Sep 2025 Performance, Pipeline Update, Outlook
YTD Sep 2025 Performance Pipeline Update Outlook
Slide 11: Further pipeline progression through 89bio acquisition
Further pipeline progression through 89bio acquisition* Prioritization of high-impact projects while increasing the total portfolio value Portfolio evolution (NME additions / removals) Portfolio value Average peak sales per pipeline project, CHF bn1 8 -8 +57% 81 4 -3 1 FGF21 analog -5 in MASH* 3 -4
Slide 12: 10 NMEs new to Ph III in 2025
10 NMEs new to Ph III in 2025 5 Ph III decisions taken in Q3: CT-388, CT-868, zilebesiran, cevostamab and HER2 TKI NXT007 in cevostamab in HER2 TKI in trontinemab in prasinezumab in zosurabalpin in zilebesiran in CT-388 in CT-868 in pegozafermin in hemophilia A R/R MM HER2+ BC AD PD MDR bacterial in
Slide 13: Overall portfolio shift after introduction of the Bar
Overall portfolio shift after introduction of the Bar Total portfolio value +27% since FY ’23 while 55% of clinical pipeline now consisting of post Bar assets Risk-reward profile of assets with Ph III Go decisions pre vs. post Bar1 Portfolio composition (# of NMEs)2 illustrative 37 20 Includes Ph II
Slide 14: 2025 Pharma pipeline: Q3 newsflow
2025 Pharma pipeline: Q3 newsflow Up to 19 NMEs with launch potential by 2030 0.5-1bn peak sales 1-2bn peak sales afimkibart 2-3bn peak sales >3bn peak sales CT-388 IBD, AtD, RA, MASH Obesity +/- T2D sefaxersen CT-868 IgAN T1D with BMI ≥25 zosurabalpin CT-996 Bacterial infections Obesity +/- T2D pet
Slide 15: Roche Diagnostics: Key technologies to drive future growth
Roche Diagnostics: Key technologies to drive future growth New SBX data at ASHG, including GUINNESS WORLD RECORDSTM title for fastest DNA sequencing technique AXELIOS 1: Roche sequencing solution Accu-Chek® SmartGuide cobas® i601 Mass Spec Molecular Lab Near Patient Care Core Lab Roche sequencing so
Slide 16: YTD Sep 2025 Performance, Pipeline Update, Outlook
YTD Sep 2025 Performance Pipeline Update Outlook
Slide 17: A solid base to deliver long-lasting future growth
A solid base to deliver long-lasting future growth Emerging pipeline complemented by business development to add significant upside potential illustrative Business development ▪ BD to accelerate pipeline rejuvenation ▪ In-house pipeline with upside potential Pharma pipeline ▪ Today’s on-market Pharm
Slide 18: 2025 guidance raised
2025 guidance raised LOE impact of CHF 0.8bn (CER, updated from CHF 1.0bn) expected for 2025 Group sales growth1 Mid single digit sales growth High single digit to low double digit Core EPS growth Core EPS growth1 (from high single digit growth) Dividend outlook Further increase dividend in Swiss fr
Slide 19: Finance
Finance Alan Hippe Chief Financial Officer
Slide 20: YTD Sep 2025: Group growth +7% at CER
YTD Sep 2025: Group growth +7% at CER Pharma Division driving Group growth +7% at CER CHFm +608 +3,399 -474 -517 -2,138 44,984 45,862 2024 Pharma LOE Dia China Fx 2025 (excl. LOE) (excl. China) healthcare pricing reforms CER: Constant exchange rates (avg. full year 2024); LOE: Loss of exclusivity in
Slide 21: Exchange rate impact on sales growth
Exchange rate impact on sales growth Negative impact mainly driven by the USD, CNY (APAC), EUR and ARS, BRL, MXN in LATAM -0.3%p -0.7%p -2.3%p CER CHF sales growth sales growth 2025 +6.7% 2025 vs. vs. -0.8%p 2024 2024 -0.1%p -0.5%p +2.0% CER EUR APAC USD LATAM JPY Other CHF CER: Constant exchange ra
Slide 22: Expected 2025 currency impact
Expected 2025 currency impact USD / CHF Assumed avg. YTD 2025 +3% -3% -4% -6% Assuming the 30 September 2025 exchange rates remain 0.90 0.89 stable until end of 2025, 0.88 0.88 2025 impact1 is expected to be (%p): 0.87 0.86 0.84 0.83 Q1 Q2 Q3 Q4 0.91 0.90 0.88 0.84 0.83 0.82 0.80 0.81 0.80 0.80 0.80
Slide 23: 2025 guidance raised
2025 guidance raised LOE impact of CHF 0.8bn (CER, updated from CHF 1.0bn) expected for 2025 Group sales growth1 Mid single digit sales growth High single digit to low double digit Core EPS growth Core EPS growth1 (from high single digit growth) Dividend outlook Further increase dividend in Swiss fr
Slide 24: Pharmaceuticals Division
Pharmaceuticals Division Teresa Graham CEO Roche Pharmaceuticals
Slide 25: YTD Sep 2025: Pharmaceuticals sales
YTD Sep 2025: Pharmaceuticals sales Strong growth across all regions YTD Sep YTD Sep 2025 2024 Change in % CHFm CHFm CHF CER Pharmaceuticals Division 35,555 34,257 4 9 United States 18,798 18,166 3 8 Europe 6,818 6,613 3 5 Japan 2,139 2,083 3 5 International 7,800 7,395 5 ##### 13 CER: Constant exch
Slide 26: YTD Sep 2025: Diversified set of key growth drivers
YTD Sep 2025: Diversified set of key growth drivers Phesgo, Xolair, Hemlibra, Vabysmo, Ocrevus and Polivy driving growth Phesgo 54% Xolair 34% Hemlibra 12% Vabysmo 13% Ocrevus 7% Polivy 40% Xofluza 163% Evrysdi 8% Columvi 81% Alecensa 8% Gazyva 13% Elevidys 64% Itovebi n/a Enspryng 26% Actemra / RoA
Slide 27: Oncology growing +2% driven by the HER2+ franchise
Oncology/Hematology Oncology growing +2% driven by the HER2+ franchise Positive Ph III (evERA) giredestrant in post-CDK4/6i ER+ mBC; HER2 TKI entering Ph II/III in HER2+ BC Q3 update Itovebi Avastin CHF 68m / N/A ▪ Phesgo: Global conversion rate climbing to 51%* CHF 763m / -15% Others ▪ Perjeta: Con
Slide 28: Giredestrant: Positive Ph III (evERA) in ESR1m and ITT
Oncology/Hematology Giredestrant: Positive Ph III (evERA) in ESR1m and ITT post-CDKi ER+ mBC Potential to be the first only-oral SERD combination therapy in the post-CDKi setting Ph III (evERA) INV-PFS results in post CDK4/6i ER+/HER2- mBC1 ESR1m population ITT population Giredestrant + SOC ET + Gir
Slide 29: Giredestrant: Ph III (evERA) shows manageable safety profile
Oncology/Hematology Giredestrant: Ph III (evERA) shows manageable safety profile Well-tolerated and safety profile aligned with individual drug profiles; no photopsia Ph III (evERA) safety in post CDK4/6i ER+/HER2- mBC1 Giredestrant + everolimus SOC ET + everolimus n = 182 n = 186 Giredestrant: 7.11
Slide 30: Polivy US patient share in 1L DLBCL reaching 35%
Oncology/Hematology Polivy US patient share in 1L DLBCL (IPI 0-5) reaching 35% Hemlibra with continued global growth; cevostamab entering Ph III in R/R MM Q3 update Lunsumio Columvi CHF 77m / +47% ▪ Hemlibra: Increasing adoption in non-inhibitor patients CHF 202m / +81% PiaSky ▪ Polivy: Strong 1L DL
Slide 31: Ocrevus: ~50% of SC starts in the US are new to brand
Neurology Ocrevus: ~50% of SC starts in the US are new to brand Trontinemab: Ph III in pre-clinical AD to be initiated; FPI achieved for Ph III (TRONTIER 1/2) in early AD Q3 update Elevidys Others ▪ Ocrevus: >12,500 patients on Ocrevus SC globally CHF 221m / +64% CHF 284m / 0% ▪ US: 60% of SC volume
Slide 32: Xolair with continued strong launch in food allergy
Immunology Xolair with continued strong launch in food allergy Gazyva achieved US approval in lupus nephritis Q3 update ▪ Xolair: Strong food allergy launch with >85k patients on treatment Others CHF 680m / +4% Actemra ▪ Biosimilar launch expected end of 2026 CHF 1,893m / +2% ▪ Actemra: Q3 biosimila
Slide 33: Vabysmo remains impacted by US branded market contraction
Ophthalmology Vabysmo remains impacted by US branded market contraction Ph III results for vamikibart in UME and satralizumab in TED to be discussed with health authorities Q3 update Luxturna CHF 39m / +178% Susvimo ▪ Vabysmo: Continued market share gains across early launch Lucentis CHF 6m / +117%
Slide 34: Vamikibart in UME: Ph III results show vision improvement
Ophthalmology Vamikibart in UME: Ph III results show vision improvement Novel targeted treatment strategy may offer a nonsteroid IVT treatment option for UME patients Ph III (MEERKAT/SANDCAT) results1 Primary endpoint Secondary endpoints * Proportion of pts with ≥ 15 letter BCVA gain from baseline i
Slide 35: Satralizumab in TED: Ph III shows differentiated benefit-risk profile
Ophthalmology Satralizumab in TED: Ph III shows differentiated benefit-risk profile Potentially first IL-6R inhibitor for active and inactive TED with convenient subcutaneous dosing Ph III (SatraGO-1/2) results: Primary endpoint and safety1 Proptosis response at Week 24 (active TED) Safety (active +
Slide 36: CVRM pipeline: CT-388, CT-868 and zilebesiran new to Ph III
Cardiovascular, Renal & Metabolism CVRM pipeline: CT-388, CT-868 and zilebesiran new to Ph III Clinical development Q3 update ▪ Pegozafermin in MASH: Potential for BID Indication Asset Ph I Ph II Ph III ▪ Ph III (ENLIGHTEN fibrosis) in MASH (F2-3) readout in H1 ’27 Hypertension zilebesiran KARDIA-1/
Slide 37: Pegozafermin: Potential best-in-disease therapy in MASH
Cardiovascular, Renal & Metabolism Pegozafermin: Potential best-in-disease therapy in MASH Further strengthens CVRM portfolio and offers optionality for future combination development Pegozafermin1 Ph II (ENLIVEN) week 24 results in pts with MASH and fibrosis (F2-F4)2* Fibrosis improvement ≥ 1stage
Slide 38: 2025: Significant key newsflow ahead
2025: Significant key newsflow ahead* Compound Indication Milestone Itovebi + palbociclib + fulvestrant 1L PIK3CA-mut HR+ BC EU approval Columvi + GemOx 2L+ DLBCL US/EU approval / (US/EU) Lunsumio SC 3L+ FL US approval/EU filing (EU filing) Elevidys DMD EU approval Regulatory Gazyva Lupus nephritis
Slide 39: Diagnostics Division
Diagnostics Division Matt Sause CEO Roche Diagnostics
Slide 40: YTD Sep 2025: Diagnostics sales
YTD Sep 2025: Diagnostics sales Diagnostics growing at +1%, China healthcare pricing reforms continue CER: Constant exchange rates (avg. full year 2024) 40
Slide 41: YTD Sep 2025: Diagnostics highlights
YTD Sep 2025: Diagnostics highlights Diagnostics growing at +1%, China healthcare pricing reforms continue CHFbn YoY CER growth ▪ Immunodiagnostics (-5%) Core Lab -1% ▪ Clinical Chemistry (+6%) ▪ Infectious diseases (0%) Molecular Lab +4% ▪ Blood Screening (+5%) Near Patient ▪ BGM (-2%) -4% ▪ Liat P
Slide 42: YTD Sep 2025: Diagnostics regional sales
YTD Sep 2025: Diagnostics regional sales Strong growth in Latin America, North America, and EMEA North America +7% EMEA ~32% of divisional sales +6% ~36% of divisional sales Asia Pacific Latin America -15% +14% ~25% of divisional sales ~7% of divisional sales Growth rates at constant exchange rates
Slide 43: AXELIOS 1: Roche Sequencing solution
AXELIOS 1: Roche Sequencing solution World’s fastest whole human genome sequencing to date Whole genome sequencing with SBX1 Context ▪ Unmet need: Rapid genetic diagnosis is key in critical care; yet current sequencing methods require multiple days SBX-D Xpandomer Variant ▪ Study objective: Investig
Slide 44: AXELIOS 1: Roche Sequencing solution
AXELIOS 1: Roche Sequencing solution Significant progress across research workflows including methylation and RNA-sequencing Methylation SBX Simplex Longer RNA sequencing1 Fraction of Isoforms Detected 100% 99.3% ATCG Library Prep TAPS Conversion Base calling (TPM > 0.05) True variant 95% 94.6% 93.8
Slide 45: Elecsys pTau181 CE mark and FDA clearance
Neurology Elecsys® pTau181 CE mark and FDA clearance First FDA cleared blood-based test to rule out Alzheimer's disease in primary care Elecsys® pTau1811 Market needs and opportunity ▪ High Burden: Alzheimer's is the leading cause of dementia, a condition projected to reach 80m by 20302 Patients wit
Slide 46: Elecsys pTau217 study readouts
Neurology Elecsys® pTau217 study readouts Study results support broad implementation of Elecsys® pTau217 in routine clinical practice Roche internal study results External customer study results Effect of pre-analytical variation on clinical ROC-AUC analysis across pTau217 solutions2 performance1 ▪
Slide 47: Diagnostics key launches 2025
Diagnostics key launches 2025 Area Product Description Market Status Elecsys® pTau 181 Non-invasive blood-based biomarker to enable earlier detection and rule out amyloid pathology CE Elecsys® Troponin-T hs High-sensitive test with greater precision at lower measurement ranges, enabling HCPs to conf
Slide 48: Roche Group development pipeline
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 49: Changes to the development pipeline
Changes to the development pipeline Q3 2025 update New to phase I New to phase II New to phase III New to registration 1 NME: 2 NMEs: 3 NMEs: 1 NME (EU): CHU pan-KRAS inhibitor (AUBE00) – solid tumors RG6652 GLP-1 RA (CT-996) - obesity +/- T2D RXXXX1,2 pegozafermin - MASH with fibrosis RG6321 Susvim
Slide 50: Roche Group development pipeline
Roche Group development pipeline Phase I (38 NMEs + 7 AIs) Phase II (17 NMEs + 6 AIs) RG6026 Columvi monotherapy + combos heme tumors RG6382 CD19 x CD3 SLE RG6171 giredestrant endometrial cancer RG6076 englumafusp alfa combos heme tumors RG6377 - IBD RG6180 autogene cevumeran solid tumors RG6114 Ito
Slide 51: Roche Group development pipeline
Roche Group development pipeline Phase III (10 NMEs + 28 AIs) Registration US & EU (3AIs) RG3502 Kadcyla + T HER-2+ eBC high-risk RG6149 astegolimab COPD RG7828 Lunsumio SC 3L+ FL RG6013 Hemlibra Type 3 VWD RG6299 sefaxersen (ASO factor B) IgA nephropathy RG7159 Gazyva1 lupus nephritis Columvi + Pol
Slide 52: Expected regulatory submissions
Itovebi + CDK4/6i + letrozole RG6114 Expected regulatory submissions* 1L ES PIK3CA-mut. HR+ HER2- advanced BC autogene cevumeran New Molecular Entities: Lead and additional indications RG6180 solid tumors prasinezumab FIXa x FX (NXT007) RG7935 RG6512 Parkinson’s hemophilia New Molecular Entity (NME)
Slide 53: Expected regulatory submissions
Expected regulatory submissions* Marketed products: Additional indications New Molecular Entity (NME) Cardiovascular, Renal & Metabolism Additional Indication (AI) Neurology Oncology / Hematology Ophthalmology Immunology Other PiaSky RG6107 aHUS Tecentriq ✓ Indicates submission to health authorities
Slide 54: Major pending approvals 2025
Major pending approvals 2025 US EU China Japan-Chugai Xofluza Lunsumio SC Polivy + chemo Tecentriq RG6152 influenza direct transmission RG7828 3L+FL RG7596 r/r DLBCL RG7446 unresectable thymic carcinoma Filed Nov 2024 Filed Nov 2024 Filed May 2025 Filed May 2025 Lunsumio SC Gazyva Lunsumio + Polivy
Slide 55: Major granted approvals 2025
Major granted approvals 2025 US EU China Japan-Chugai TNKase Columvi + chemo Lunsumio Tecentriq RG3625 stroke RG6026 2L DLBCL RG7828 3L+ FL RG7446 Alveolar Soft Part Sarcoma Feb 2025 April 2025 Dec 2024 Feb 2025 Susvimo Xofluza Itovebi + palbociclib + fulvestrant Elevidys RG6321 DME RG6152 influenza
Slide 56: Roche Group development pipeline
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 57: Alecensa (alectinib)
Alecensa (alectinib, RG7853) CNS-active inhibitor of anaplastic lymphoma kinase Indication Adjuvant ALK+ NSCLC Phase III Phase/study ALINA # of patients N=257 Oncology/Hematology ▪ ARM A: Alecensa 600mg BID Design ▪ ARM B: Platinum-based chemotherapy Primary endpoint ▪ Disease-free survival ▪ FPI Q3
Slide 58: Itovebi (inavolisib)
Itovebi (inavolisib, RG6114, GDC-0077) A potent, orally available, and selective PI3Kα inhibitor PIK3CA-mutant HR-positive metastatic post CDKi HR-positive PIK3CA-mutant breast PIK3CA mutant solid tumors and metastatic Indication breast cancer (mBC) cancer ER+ HER2-negative breast cancer Phase III P
Slide 59: Itovebi (inavolisib)
Itovebi (inavolisib, RG6114, GDC-0077) A potent, orally available, and selective PI3Kα inhibitor 1L endocrine-sensitive PIK3CA-mutated HR+, HER2-, advanced breast Indication 1L HER2-positive PIK3CA mutant metastatic breast cancer (mBC) cancer Phase III Phase III Phase/study INAVO122 INAVO123 # of pa
Slide 60: Kadcyla (trastuzumab emtansine)
Kadcyla (trastuzumab emtansine, RG3502) First ADC for HER2-positive breast cancer HER2-positive early breast cancer (BC) HER2-positive early breast cancer (BC) Indication high-risk patients high-risk patients Phase III Phase III Phase/study KATHERINE ASTEFANIA # of patients N=1,484 N=1150 ▪ ARM A: K
Slide 61: Tecentriq (atezolizumab) lung cancer
Tecentriq (atezolizumab, RG7446) Anti-PD-L1 cancer immunotherapy – lung cancer Indication Periadjuvant NSCLC 1L maintenance extensive-stage SCLC Phase III Phase III Phase/study IMpower030 IMforte1 # of patients N=450 N=450 Oncology/Hematology ▪ ARM A: Tecentriq plus platinum-based chemotherapy ▪ ARM
Slide 62: Tecentriq (atezolizumab) urothelial carcinoma
Tecentriq (atezolizumab, RG7446) Anti-PD-L1 cancer immunotherapy – urothelial carcinoma High-risk non-muscle-invasive ctDNA+, high-risk muscle-invasive Indication bladder cancer (NMIBC) bladder cancer (MIBC) Phase III Phase III Phase/study ALBAN IMvigor011 # of patients N=516 N=240 ARM A: BCG induct
Slide 63: Columvi (glofitamab)
Columvi (glofitamab, RG6026) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication Relapsed or refractory Non-Hodgkin’s lymphoma (NHL) Phase/study Phase I Phase Ib Phase I # of patients N=700 N=140 N=18-36 Cohort 1: Single-agent dose escalation study Dose escalation and
Slide 64: Columvi (glofitamab)
Columvi (glofitamab, RG6026) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication Non-Hodgkin’s lymphoma (NHL) 2L+ SCT-ineligible DLBCL Phase III Phase/study Phase Ib STARGLO Part I: 15-60 # of patients N=270 Part II: ~66-104 ▪ Part I: Dose-finding for the combination o
Slide 65: Columvi (glofitamab)
Columvi (glofitamab, RG6026) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication 2L+ SCT-eligible DLBCL 2L+ SCT-ineligible DLBCL 1L DLBCL fit (IPI 2-5) Phase III Phase/study Phase Ib Phase Ib SKYGLO # of patients N=40 N=112 N=1130 ▪ Columvi plus R-ICE (single-arm study
Slide 66: Columvi (glofitamab)
Columvi (glofitamab, RG6026) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication Relapsed or refractory mantle cell lymphoma (MCL) Phase III Phase/study GLOBRYTE # of patients N=182 ▪ ARM A: Columvi monotherapy Oncology/Hematology ▪ ARM B: Bendamustine + rituximab or r
Slide 67: Lunsumio (mosunetuzumab)
Lunsumio (mosunetuzumab, RG7828) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication 3L+ FL, 3L+ DLBCL & other relapsed or refractory NHL Relapsed or refractory LBCL & MCL Phase/study Phase I/II Phase Ib/II # of patients N=713 N=235 ▪ Dose escalation of Lunsumio monoth
Slide 68: Lunsumio (mosunetuzumab)
Lunsumio (mosunetuzumab, RG7828) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication 2L+ SCT ineligible DLBCL Phase III Phase/study SUNMO # of patients N=222 ▪ ARM A: Lunsumio plus Polivy Oncology/Hematology ▪ ARM B: R + GemOx Design ▪ Progression-free survival Primary
Slide 69: Lunsumio (mosunetuzumab)
Lunsumio (mosunetuzumab, RG7828) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication 1L DLBCL & 2L DLBCL following 1L induction FL Phase/study Phase I/II Phase Ib/II # of patients N=187 N=183 ▪ Cohort A: Lunsumio monotherapy (after a response to prior systemic Non-Rand
Slide 70: Lunsumio (mosunetuzumab)
Lunsumio (mosunetuzumab, RG7828) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication 2L+ FL Relapsed or refractory CLL Phase III Phase/study Phase Ib/II CELESTIMO # of patients N=474 N=137 ▪ ARM A: Lunsumio plus lenalidomide ▪ Lunsumio monotherapy (3L+ CLL) Oncology/He
Slide 71: Polivy (polatuzumab vedotin)
Polivy (polatuzumab vedotin, RG7596) ADC targeting CD79b to treat B cell malignancies Indication 1L DLBCL Phase III Phase/study POLARIX # of patients N=879 Oncology/Hematology ▪ ARM A: Polivy plus R-CHP ▪ ARM B: R-CHOP Design ▪ Progression-free survival Primary endpoint ▪ Data presented at ASH 2021
Slide 72: Venclexta (venetoclax)
Venclexta (venetoclax, RG7601) Novel small molecule Bcl-2 selective inhibitor – chronic lymphocytic leukemia Indication Untreated fit chronic lymphocytic leukemia (CLL) patients Phase III Phase/study CristaLLo # of patients N=166 Oncology/Hematology ▪ ARM A: Venclexta plus Gazyva ▪ ARM B: Fludarabin
Slide 73: Hemlibra (emicizumab)
Hemlibra (emicizumab, RG6013) Factor VIII mimetic for treatment of hemophilia A Indication Type 3 Von Willebrand disease (VWD) Phase III Phase/study WILL-EMI # of patients N=66 Open-label in participants aged 2 years and above diagnosed with Type 3 von Willebrand disease (VWD) on prior SOC on demand
Slide 74: PiaSky (crovalimab)
PiaSky (crovalimab, RG6107, SKY59) A humanized monoclonal antibody against complement C5 Indication Paroxysmal nocturnal hemoglobinuria (PNH) patients switching from a C5 inhibitor Phase III Phase/study COMMODORE 1 # of patients N=89 (ARMs A/B) ▪ ARM A: PiaSky ARM B: Eculizumab Oncology/Hematology ▪
Slide 75: PiaSky (crovalimab)
PiaSky (crovalimab, RG6107, SKY59) A humanized monoclonal antibody against complement C5 Paroxysmal nocturnal hemoglobinuria (PNH) Paroxysmal nocturnal hemoglobinuria (PNH) Indication C5 inhibitor naive patients C5 inhibitor naive patients (China only) Phase III Phase III Phase/study COMMODORE 2 COM
Slide 76: PiaSky (crovalimab)
PiaSky (crovalimab, RG6107, SKY59) A humanized monoclonal antibody against complement C5 Atypical hemolytic uremic syndrome (aHUS) Atypical hemolytic uremic syndrome (aHUS) Indication - adults - paediatric Phase III Phase III Phase/study COMMUTE-a COMMUTE-p # of patients N=90 N=35 Single-arm study o
Slide 77: PiaSky (crovalimab)
PiaSky (crovalimab, RG6107, SKY59) A humanized monoclonal antibody against complement C5 Sickle cell disease (SCD) Sickle cell disease (SCD) Indication acute treatment chronic VOC prevention Phase Ib Phase IIa Phase/study CROSSWALK-a CROSSWALK-c # of patients N=30 N=90 Oncology/Hematology ▪ ARM A: P
Slide 78: Elevidys
Elevidys (delandistrogene moxeparvovec, RG6356, SRP-9001) rAAVrh74.MHCK7.Micro-dystrophin gene therapy Indication Duchenne muscular dystrophy (DMD) Phase II Phase/study ENVOL # of patients N=21 Neurology Open label single arm study in 0 to <4 year old DMD boys who will receive a single intravenous (
Slide 79: Enspryng (satralizumab)
Enspryng (satralizumab, RG6168, SA237) Anti-IL-6 receptor humanized monoclonal antibody Myelin oligodendrocyte glycoprotein antibody Indication Autoimmune encephalitis (AIE) Duchenne Muscular Dystrophy (DMD) disease (MOG-AD) Phase III Phase III Ph II Phase/study METEOROID CIELO SHIELD DMD # of patie
Slide 80: Evrysdi (risdiplam)
Evrysdi (risdiplam, RG7916) Oral SMN2 splicing modifier Indication Spinal muscular atrophy (SMA) Phase II Phase II Phase/study RAINBOWFISH JEWELFISH # of patients N=25 N=174 ▪ Infants aged from birth to 6 weeks who have been genetically ▪ Adult and pediatric patients with previously treated SMA type
Slide 81: Ocrevus (ocrelizumab)
Ocrevus (ocrelizumab, RG1594) Humanized monoclonal antibody selectively targeting CD20+ B cells Indication Primary progressive multiple sclerosis (PPMS) Phase IIIb Phase/study ORATORIO-HAND # of patients N ~ 1,000 Neurology 120-week treatment period: ▪ ARM A: Ocrevus 600mg IV Q24W ▪ ARM B: Placebo D
Slide 82: Ocrevus (ocrelizumab)
Ocrevus (ocrelizumab, RG1594) Humanized monoclonal antibody selectively targeting CD20+ B cells Indication Primary progressive multiple sclerosis (PPMS) Relapsing multiple sclerosis (RMS) PPMS & RMS Phase IIIb Phase IIIb Phase III Phase/study GAVOTTE MUSETTE Ocarina II1 # of patients N ~ 699 N ~ 786
Slide 83: Gazyva (obinutuzumab)
Gazyva (obinutuzumab, RG7159) Humanized anti-CD20 monoclonal antibody; immunology development program Indication Lupus nephritis Membranous nephropathy Phase II Phase III Phase III Phase/study NOBILITY REGENCY MAJESTY # of patients N=126 N=252 N=140 ▪ ARM A: Gazyva 1000mg IV plus MMF / ▪ ARM A: Gazy
Slide 84: Gazyva (obinutuzumab)
Gazyva (obinutuzumab, RG7159) Humanized anti-CD20 monoclonal antibody; immunology development program Indication Systemic lupus erythematosus (SLE) Childhood onset idiopathic nephrotic syndrome* Phase III Phase III Phase/study ALLEGORY INShore # of patients N=300 N=80 ▪ ARM A: Gazyva 1000mg IV on Da
Slide 85: Lunsumio in SLE
Lunsumio (mosunetuzumab, RG7828, CD20 x CD3) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication Systemic lupus erythematosus (SLE) Phase/study Phase I # of patients N=15 ▪ ARM A: Lunsumio SC on either Day 1 or on Days 1 and 8 Immunology ▪ ARM B: Fractionated (divided)
Slide 86: Xolair (omalizumab)
Xolair (omalizumab, RG3648) Humanized monoclonal antibody that selectively binds to IgE Indication Food allergy Phase III Phase/study OUtMATCH1 # of patients N=180 ▪ Xolair by SC injection either Q2W or Q4W for 16 to 20 weeks Immunology Design Primary endpoint ▪ Proportion of participants that succe
Slide 87: Enspryng in thyroid eye disease
Enspryng (satralizumab, RG6168, SA237) Anti-IL-6 receptor humanized monoclonal antibody Indication Thyroid eye disease Phase III Phase III Phase/study SatraGo-1 SatraGo-2 # of patients N=120 N=120 ▪ ARM A: Satralizumab at weeks 0, 2, 4 (loading doses) and maintenance ▪ ARM A: Satralizumab at weeks 0
Slide 88: Susvimo (PDS)
Susvimo (PDS, RG6321) First eye implant to achieve sustained delivery of a biologic medicine Indication Wet age-related macular degeneration (wAMD) Phase III Phase II+III extension Phase IIIb Phase/study Archway Portal Velodrome # of patients N=418 N=1,000 N=442 ▪ ARM A: PDS 100mg/mL Q24W ▪ Ex-LADDE
Slide 89: Susvimo (PDS)
Susvimo (PDS, RG6321) First eye implant to achieve sustained delivery of a biologic medicine Diabetic retinopathy (DR) without Indication Diabetic macular edema (DME) center-involved diabetic macular edema (DME) Phase III Phase III Phase/study Pagoda Pavilion # of patients N=634 N=174 ▪ ARM A: Intra
Slide 90: Vabysmo (faricimab)
Vabysmo (faricimab, RG7716) Bispecific antibody for the eye which targets and inhibits two signaling pathways (Ang-2 and VEGF-A) Indication Center-involving diabetic macular edema (CI-DME) Phase III Phase III Phase/study YOSEMITE RHINE # of patients N=940 N=951 ▪ ARM A: Vabysmo 6.0 mg Q8W ▪ ARM A: V
Slide 91: Vabysmo (faricimab)
Vabysmo (faricimab, RG7716) Bispecific antibody for the eye which targets and inhibits two signaling pathways (Ang-2 and VEGF-A) Indication Wet age related macular degeneration (wAMD) Phase III Phase III Phase/study TENAYA LUCERNE # of patients N=671 N=658 ▪ ARM A: Vabysmo 6.0mg Q16W flexible after
Slide 92: Vabysmo (faricimab)
Vabysmo (faricimab, RG7716) Bispecific antibody for the eye which targets and inhibits two signaling pathways (Ang-2 and VEGF-A) Indication Macular edema (ME) secondary to branch retinal vein occlusion (RVO) Macular edema (ME) secondary to central retinal vein occlusion (RVO) Phase III Phase III Pha
Slide 93: Vabysmo (faricimab)
Vabysmo (faricimab, RG7716) Bispecific antibody for the eye which targets and inhibits two signaling pathways (Ang-2 and VEGF-A) Indication Myopic choroidal neovascularization (CNV) Phase III Phase/study POYANG # of patients n=280 Ophthalmology ▪ ARM A: Vabysmo 6.0 mg Q4W PRN ▪ ARM B: Ranibizumab 0.
Slide 94: Xofluza (baloxavir marboxil)
Xofluza (baloxavir marboxil, RG6152, S-033188) Small molecule, novel CAP-dependent endonuclease inhibitor Indication Influenza Phase III Phase III Phase IIIb Phase/study miniSTONE 1 (0-1 year old) miniSTONE 2 (1- <12 years old ) CENTERSTONE # of patients N=30 N=176 N=3,160 Healthy pediatric patients
Slide 95: Roche Group development pipeline
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 96: Divarasib (KRAS G12C inhibitor)
Divarasib (KRAS G12C inhibitor, RG6330, GDC-6036) A potent, orally available, and selective inhibitor of the KRAS G12C mutant protein Indication 1L NSCLC 2L NSCLC 1L NSCLC Phase Ib/II Phase III Phase III Phase/study KRASCENDO 170 KRASCENDO 1 KRASCENDO 2 # of patients N=60 N=320 N=600 ▪ Cohort A: Com
Slide 97: Divarasib (KRAS G12C inhibitor)
Divarasib (KRAS G12C inhibitor, RG6330, GDC-6036) A potent, orally available, and selective inhibitor of the KRAS G12C mutant protein Indication Advanced or metastatic solid tumors with a KRAS G12C mutation 1L metastatic colorectal cancer (mCRC) Phase Ib Phase/study Phase I INTRINSIC # of patients N
Slide 98: Giredestrant (SERD)
Giredestrant (SERD (3), RG6171, GDC-9545) A selective estrogen receptor degrader or downregulator Indication ER+ HER2-negative metastatic breast cancer (mBC) Phase/study Phase I # of patients N=181 ▪ Dose escalation and expansion at RPTD ▪ Giredestrant monotherapy and in combination with palbociclib
Slide 99: Giredestrant (SERD)
Giredestrant (SERD (3), RG6171, GDC-9545) A selective estrogen receptor degrader or downregulator Indication Grade 1 endometrial cancer 1L ER-positive metastatic breast cancer (mBC) Adjuvant ER-positive breast cancer (BC) Phase II Phase III Phase III Phase/study endomERA persevERA Breast Cancer lidE
Slide 100: Giredestrant (SERD)
Giredestrant (SERD (3), RG6171, GDC-9545) A selective estrogen receptor degrader or downregulator post-CDK4/6 ER-positive/HER2-negative 1L ER-positive/HER2-positive breast cancer ET resistant ER+/HER2-negative breast cancer Indication breast cancer (BC) (BC) (BC) Phase III Phase III Phase III Phase/
Slide 101: NXT007 (FIXa x FX)
NXT007 (FIXa x FX, RG6512) Bispecific antibody which targets Factor IXa and Factor X Indication Severe or Moderate Hemophilia A Phase I/II Phase/study (multiple-ascending dose) # of patients N=40 Oncology/Hematology ▪ Two loading doses of NXT007 SC (Q2W) followed by Q4W maintenance dosing Design ▪ S
Slide 102: Emugrobart
Emugrobart (RG6237, GYM 329) Recycling and antigen-sweeping monoclonal anti-latent myostatin antibody Indication Facioscapulohumeral Muscular Dystrophy (FSHD) Spinal muscular atrophy (SMA) Phase II Phase II/III Phase/study MANOEUVRE MANATEE1 # of patients N=48 N=259 ▪ 4w baseline movement data colle
Slide 103: Emugrobart
Emugrobart (RG6237, GYM 329) Recycling and antigen-sweeping monoclonal anti-latent myostatin antibody Indication Obesity Phase II Phase/study Phase Ib GYMINDA # of patients N=30-36 N=234 ▪ Cohort A (n=15-18): Single dose emugrobart 50mg SC ▪ 48w DB Tx period: ▪ Cohort B (n=15-18): Multiple dosing 18
Slide 104: Fenebrutinib
Fenebrutinib (RG7845, GCD-0853) Highly selective and reversible (noncovalent) bruton tyrosine kinase Indication Relapsing multiple sclerosis (RMS) Phase III Phase III Phase II (Biomarker study) Phase/study FENhance 1 FENhance 2 FENopta # of patients N=746 N=751 N=109 ARM A: Fenebrutinib twice daily
Slide 105: Fenebrutinib
Fenebrutinib (RG7845, GCD-0853) Highly selective and reversible (noncovalent) bruton tyrosine kinase Indication Primary progressive multiple sclerosis (PPMS) Phase III Phase/study FENtrepid # of patients N=985 Neurology ▪ ARM A: Fenebrutinib twice daily oral ▪ ARM B: Ocrevus 2x300mg IV Q24W Design ▪
Slide 106: Prasinezumab
Prasinezumab (anti-αSynuclein; RG7935) Anti-alpha-synuclein antibody under investigation for Parkinson’s disease Indication Early-stage Parkinson's disease PASADENA PADOVA PARAISO Phase/study Phase II Phase IIb Phase III # of patients 316 586 N=900 ▪ PART 1:ARM A: Prasinezumab IV Q4W (low dose) ▪ AR
Slide 107: Tominersen (HTT ASO)
Tominersen (HTT ASO, RG6042) Antisense oligonucleotide (ASO) targeting human HTT mRNA Indication Huntington’s disease Phase II Phase/study GENERATION HD2 # of patients N=300 Neurology Patients aged 25 to 50 years with prodromal (very early subtle signs of HD) or early manifest HD ▪ ARM A: Tominersen
Slide 108: Trontinemab
Trontinemab (BS-anti-Aβ mAb, RG6102) A novel BrainshuttleTM bispecific 2+1 monoclonal antibody targeting Aβ Prodromal or mild to moderate Alzheimer's Indication Early Alzheimer's Disease Disease Phase III Phase III Phase/study Phase I/II TRONTIER 1 TRONTIER 2 # of patients N=210 N=800 N=800 Neurolog
Slide 109: Astegolimab (Anti-ST2)
Astegolimab (Anti-ST2, RG6149) A monoclonal antibody that selective binds to ST2 Indication Chronic obstructive pulmonary disease (COPD) Phase IIb Phase III Phase/study ALIENTO ARNASA # of patients N=1,290 N=1,290 ▪ ARM A: SC astegolimab Q2W ▪ ARM A: SC astegolimab Q2W ▪ ARM B: SC astegolimab Q4W ▪
Slide 110: Sefaxersen (ASO factor B)
Sefaxersen (ASO factor B, RG6299) Antisense oligonucleotide that targets factor B Indication IgA nephropathy (IgAN) Phase III Phase/study Phase II* IMAGINATION # of patients N=23 N=428 ▪ Sefaxersen SC at week 1 following Q4W dosing through week 25 ▪ ARM A: Sefaxersen SC at week 1, 3, 5 following Q4W
Slide 111: Afimkibart (anti-TL1A)
Afimkibart (anti-TL1A, RG6631) A monoclonal antibody targeting TL1A, blocking TH1 and TH17 pathways Indication Moderate to severe ulcerative colitis Moderate to severe ulcerative colitis Phase III Phase III Phase/study AMETRINE-1 AMETRINE-2 # of patients N=400 N=350 ▪ ARM A: Afimkibart IV induction
Slide 112: Afimkibart (anti-TL1A)
Afimkibart (anti-TL1A, RG6631) A monoclonal antibody targeting TL1A, blocking TH1 and TH17 pathways Indication Moderate to severe Crohn's Disease Phase III Phase III Phase/study SIBERITE-1 SIBERITE-2 # of patients N=600 N=425 ▪ Treat-through design with no re-randomization after induction ▪ Inductio
Slide 113: Afimkibart (anti-TL1A)
Afimkibart (anti-TL1A, RG6631) A monoclonal antibody targeting TL1A, blocking TH1 and TH17 pathways Indication Atopic dermatitis Metabolic Dysfunction-associated Steatohepatitis (MASH) Phase/study Phase II Phase Ib # of patients N=160 N=50 ▪ ARM A: High dose afimkibart SC ▪ Afimkibart IV at w0, w2,
Slide 114: Vamikibart (anti-IL-6)
Vamikibart (anti-IL-6, RG6179) A monoclonal antibody that potently binds interleukin-6 (IL-6) cytokine Indication Uveitic macular edema (UME) Phase III Phase III Phase/study MEERKAT SANDCAT # of patients N=225 N=225 ARM A: Vamikibart low-dose Q4W to week 12, followed by PRN ARM A: Vamikibart low-dos
Slide 115: CT-388 (GLP-1/GIP RA)
CT-388 (GLP-1/GIP RA, RG6640) Once-weekly subcutaneous injectable dual GLP-1/GIP receptor agonist Overweight/obesity with or without type 2 Overweight/obesity without type 2 Indication Overweight/obesity with type 2 diabetes diabetes diabetes Phase/study Phase I Phase II Phase II # of patients N=129
Slide 116: CT-996 (GLP-1 RA)
CT-996 (GLP-1 RA, RG6652) Once-daily oral small molecule GLP-1 receptor agonist Overweight/obesity with or without type 2 Indication Obesity without type 2 diabetes Glycaemic control trial with T2D participants diabetes Phase/study Phase I Phase II Phase II # of patients N=118 N=340 N=240 Cardiovasc
Slide 117: CT-868 (GLP-1/GIP RA)
CT-868 (GLP-1/GIP RA, RG6641) Once-daily subcutaneous injectable dual GLP-1/GIP receptor agonist Indication Type 1 diabetes with BMI ≥ 27 Phase/study Phase II # of patients N=96 Cardiovascular, Renal & Metabolism ▪ ARM A: CT-868 low dose ▪ ARM B: CT-868 medium dose Design ▪ ARM C: CT-868 high dose ▪
Slide 118: Roche Group development pipeline
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 119: pRED oncology development programs
pRED oncology development programs Molecule Indication Phase # of patients Status CT Identifier Oncology Part I: FPI Q3 2019 Part II: FPI Q3 2020 englumafusp alfa R/R B cell non-Hodgkin’s lymphoma I 498 Part III: FPI Q3 2024 NCT04077723 (CD19-4-1BBL, RG6076) Combination study with Columvi Data prese
Slide 120: pRED neurology development programs
pRED neurology development programs Molecule Indication Phase # of patients Status CT Identifier Neurology ISRCTN16295177 BrainshuttleTM-CD20 (RG6035) Multiple sclerosis I 119 FPI Q3 2021 NCT05704361 nivegacetor (gamma-secretase FPI Q2 2024 Alzheimer's disease II 255 NCT06402838 modulator, RG6289) R
Slide 121: pRED immunology and ophthalmology development programs
pRED immunology and ophthalmology development programs Molecule Indication Phase # of patients Status CT Identifier Immunology selnoflast* Asthma Ib 60 FPI Q1 2024 (NLRP3i, RG6418) CD19 x CD3 (RG6382) SLE I 70 FPI Q4 2023 NCT05835986 NME (RG6377) IBD I FPI Q2 2024 ISRCTN15555964 Ophthalmology zifiba
Slide 122: Roche Group development pipeline
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 123: gRED oncology development programs -1
gRED oncology development programs -1 Molecule Indication Phase # of patients Status CT Identifier Oncology FPI Q3 2017 R/R multiple myeloma I 355 LPI Q2 2023 NCT03275103 Data presented at ASH 2020-2024 R/R multiple myeloma I 120 FPI Q2 2021 NCT04910568 cevostamab BCMA-experienced R/R MM I/II 140 FP
Slide 124: gRED oncology development programs -2
gRED oncology development programs -2 Molecule Indication Phase # of patients Status CT Identifier Oncology AR degrader (RG6537)1 mCRPC I ~160 FPI Q2 2023 NCT05800665 NME (RG6468) Solid tumors I 110 FPI Q4 2023 NCT06031441 NME (RG6561) Solid tumors I 310 FPI Q4 2024 NCT06488716 KRAS G12D inhibitor (
Slide 125: gRED immunology and ophthalmology development programs
gRED immunology and ophthalmology development programs Molecule Indication Phase # of patients Status CT Identifier Immunology flizasertib Cardiac surgery associated acute II 404 FPI Q1 2025 NCT06602453 (RG6287, GDC-8264) kidney injury (CS-AKI) TMEM16A potentiator (RG6421, Muco-obstructive respirato
Slide 126: Roche Group development pipeline
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 127: YTD Sep 2025: Pharma Division sales
YTD Sep 2025: Pharma Division sales Top 20 products Global US Europe Japan International CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER Ocrevus 5,190 7 3,613 4 1,060 12 - - 517 24 Hemlibra 3,526 12 1,941 7 740 9 275 9 570 45 Vabysmo 3,063 13 2,139 4 556 24 105 26 263 115 Tecentriq 2,616 1 1,
Slide 128: YTD Sep 2025: Pharma Division sales
YTD Sep 2025: Pharma Division sales Products launched since 2015 Global US Europe Japan International CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER Cotellic 35 22 16 41 8 -6 - - 11 22 Alecensa 1,190 8 420 18 197 -8 151 8 422 7 Tecentriq 2,616 1 1,222 -3 650 2 262 -3 482 15 Ocrevus 5,190 7 3
Slide 129: YTD Sep 2025: Pharma Division sales
YTD Sep 2025: Pharma Division sales Product sales Pharmaceuticals Division Global US Europe Japan International CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER Ocrevus 5,190 7 3,613 4 1,060 12 - - 517 24 Hemlibra 3,526 12 1,941 7 740 9 275 9 570 45 Vabysmo 3,063 13 2,139 4 556 24 105 26 263 1
Slide 130: Pharma Division CER sales growth in %
Pharma Division CER sales growth1 in % Global top 20 products Q1/24 Q2/24 Q3/24 Q4/24 Q1/25 Q2/25 Q3/25 Ocrevus 8 9 11 7 6 10 6 Hemlibra 8 6 14 21 11 22 4 Vabysmo 108 81 59 43 18 19 4 Tecentriq 1 2 0 -1 0 -1 4 Perjeta -3 -1 2 9 -10 -14 -14 Xolair 10 11 12 29 26 41 34 Actemra / RoActemra -2 8 7 4 -1
Slide 131: Pharma Division CER sales growth in %
Pharma Division CER sales growth1 in % Top 20 products by region US Europe Japan International Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Ocrevus 0 3 8 1 21 11 14 12 - - - - 37 16 23 35 Hemlibra 20 0 21 -1 15 7 7 14 22 3 12 11 36 72 60 9 Vabysmo 35 7 10 -4 88 42 25 9 46 35 28 17 63 101 130 111
Slide 132: CER sales growth (%)
CER sales growth (%) Quarterly development 2024 vs. 2023 2025 vs. 2024 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Pharma Division 2 9 10 12 8 11 7 United States 5 6 9 15 6 13 5 Europe 11 10 2 10 5 5 5 Japan -45 -3 1 1 3 7 6 International 12 23 22 11 18 11 11 Diagnostics Division 2 8 6 -1 0 0 2 Roche Group 2 9 9 9 6 8 6 0
Slide 133: Ocrevus
Ocrevus Global sales CER growth Regional sales CER growth CHFbn +7% 5.4 US +4% 5.2 5.0 Europe +12% 4.8 4.6 4.4 International +24% 4.2 4.0 YTD Sep YTD Sep YTD Sep YTD Sep 2022 2023 2024 2025 YTD Sep 2025 sales of CHF 5,190m ▪ US: Moving into earlier lines displacing orals; SC launch ongoing; #1 in US
Slide 134: Hemlibra
Hemlibra Global sales CER growth Regional sales CER growth CHFbn +12% 4.0 US +7% 3.5 Europe +9% 3.0 Japan +9% 2.5 2.0 1.5 1.0 International +45% 0.5 0.0 YTD Sep YTD Sep YTD Sep YTD Sep 2022 2023 2024 2025 YTD Sep 2025 sales of CHF 3,526m ▪ US: Continued share gains in non-inhibitor patients; US impa
Slide 135: Vabysmo
Vabysmo Global sales CER growth Regional sales CER growth CHFbn +13% 3.5 US +4% 3.0 2.5 Europe +24% 2.0 1.5 Japan +26% 1.0 International +115% 0.5 0.0 YTD Sep YTD Sep YTD Sep YTD Sep 2022 2023 2024 2025 YTD Sep 2025 sales of CHF 3,063m ▪ US: Sales impacted by branded market contraction, continued ma
Slide 136: Tecentriq
Tecentriq Global sales CER growth Regional sales CER growth CHFbn +1% 3.2 US -3% 2.8 Europe +2% 2.4 Japan -3% 2.0 1.6 1.2 0.8 International +15% 0.4 0.0 YTD Sep YTD Sep YTD Sep YTD Sep 2022 2023 2024 2025 YTD Sep 2025 sales of CHF 2,616m ▪ US: Competitive pressure intensifying ▪ EU: Growth despite c
Slide 137: Perjeta
Perjeta Global sales CER growth Regional sales CER growth CHFbn -13% 3.5 US -2% 3.0 Europe -15% 2.5 Japan -39% 2.0 1.5 1.0 International -19% 0.5 0.0 YTD Sep YTD Sep YTD Sep YTD Sep 2022 2023 2024 2025 YTD Sep 2025 sales of CHF 2,316m ▪ US: Increasing conversion to Phesgo ▪ EU: Conversion to Phesgo
Slide 138: Xolair
Xolair Global sales CER growth Regional sales CER growth CHFbn +34% 2.5 2.0 US +34% 1.5 1.0 0.5 0.0 YTD Sep YTD Sep YTD Sep YTD Sep 2022 2023 2024 2025 YTD Sep 2025 sales of CHF 2,226m ▪ US: Strong food allergy launch with >85k patients on treatment; Strong CSU performance driving additional growth
Slide 139: Actemra/RoActemra
Actemra/RoActemra ra / RoActemra Global sales CER growth Regional sales CER growth CHFbn +2% 2.2 US +2% 2.0 Europe -10% 1.8 1.6 Japan +5% 1.4 1.2 1.0 0.8 0.6 International +19% 0.4 0.2 0.0 YTD Sep YTD Sep YTD Sep YTD Sep 2022 2023 2024 2025 YTD Sep 2025 sales of CHF 1,893m ▪ US: Continued growth in
Slide 140: Phesgo
Phesgo Global sales CER growth Regional sales CER growth CHFbn +54% 2.0 US +35% 1.8 Europe +13% 1.6 1.4 1.2 Japan +63% 1.0 0.8 0.6 International +193% 0.4 0.2 0.0 YTD Sep YTD Sep YTD Sep YTD Sep 2022 2023 2024 2025 YTD Sep 2025 sales of CHF 1,827m ▪ US: Strong growth driven by adjuvant BC; increasin
Slide 141: Kadcyla
Kadcyla Global sales CER growth Regional sales CER growth CHFbn +8% 1.8 US +5% 1.6 Europe -6% 1.4 1.2 Japan -2% 1.0 0.8 0.6 International +28% 0.4 0.2 0.0 YTD Sep YTD Sep YTD Sep YTD Sep 2022 2023 2024 2025 YTD Sep 2025 sales of CHF 1,531m ▪ US: Growth in adjuvant BC compensating for share decline i
Slide 142: Evrysdi
Evrysdi Global sales CER growth Regional sales CER growth CHFbn +8% 1.4 US +14% 1.2 Europe +5% 1.0 0.8 Japan +6% 0.6 0.4 International +5% 0.2 0.0 YTD Sep YTD Sep YTD Sep YTD Sep 2022 2023 2024 2025 YTD Sep 2025 sales of CHF 1,293m ▪ US: Strong uptake across all patient segments; including treatment
Slide 143: Alecensa
Alecensa Global sales CER growth Regional sales CER growth CHFbn +8% 1.4 US +18% 1.2 Europe -8% 1.0 Japan +8% 0.8 0.6 0.4 International +7% 0.2 0.0 YTD Sep YTD Sep YTD Sep YTD Sep 2022 2023 2024 2025 YTD Sep 2025 sales of CHF 1,190m ▪ US: Continued growth; Strong position in 1L ALK+ NSCLC is maintai
Slide 144: Polivy
Polivy Global sales CER growth Regional sales CER growth CHFbn +40% 1.2 US +27% Europe +63% 1.0 0.8 Japan +10% 0.6 0.4 International +94% 0.2 0.0 YTD Sep YTD Sep YTD Sep YTD Sep 2022 2023 2024 2025 YTD Sep 2025 sales of CHF 1,101m ▪ US: Strong growth following approval in 1L DLBCL ▪ EU: Strong growt
Slide 145: MabThera/Rituxan
MabThera/Rituxan Global sales CER growth Regional sales CER growth CHFbn -4% 1.8 US -2% 1.6 Europe -2% 1.4 1.2 Japan -11% 1.0 0.8 0.6 0.4 International -9% 0.2 0.0 YTD Sep YTD Sep YTD Sep YTD Sep 2022 2023 2024 2025 YTD Sep 2025 sales of CHF 933m ▪ US: Biosimilar erosion slowing ▪ EU: Biosimilar ero
Slide 146: TNKase/Activase
TNKase/Activase Global sales CER growth Regional sales CER growth CHFbn -2% 1.0 0.8 US -2% 0.6 0.4 International -13% 0.2 0.0 YTD Sep YTD Sep YTD Sep YTD Sep 2022 2023 2024 2025 YTD Sep 2025 sales of CHF 833m ▪ Spontaneous TNKase use in AIS early time window CER: Constant exchange rates 146
Slide 147: Herceptin
Herceptin Global sales CER growth Regional sales CER growth CHFbn -19% 1.8 US -9% 1.6 Europe 0% 1.4 1.2 Japan -46% 1.0 0.8 0.6 0.4 International -29% 0.2 0.0 YTD Sep YTD Sep YTD Sep YTD Sep 2022 2023 2024 2025 YTD Sep 2025 sales of CHF 817m ▪ US: Biosimilar erosion slowing; Switching of patients wit
Slide 148: Avastin
Avastin Global sales CER growth Regional sales CER growth CHFbn -15% 1.8 US -19% 1.6 Europe -14% 1.4 1.2 Japan -23% 1.0 0.8 0.6 International -10% 0.4 0.2 0.0 YTD Sep YTD Sep YTD Sep YTD Sep 2022 2023 2024 2025 YTD Sep 2025 sales of CHF 763m ▪ US: Ongoing biosimilar erosion ▪ EU: Ongoing biosimilar
Slide 149: Gazyva
Gazyva Global sales CER growth Regional sales CER growth CHFbn +13% 0.8 US +18% Europe +1% 0.6 Japan +20% 0.4 0.2 International +17% 0.0 YTD Sep YTD Sep YTD Sep YTD Sep 2022 2023 2024 2025 YTD Sep 2025 sales of CHF 728m ▪ US: Strong growth driven by combination therapies in 1L CLL ▪ EU: Growth in 1L
Slide 150: Roche Group development pipeline
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 151: YTD Sep 2025: Diagnostics Division CER growth
YTD Sep 2025: Diagnostics Division CER growth By Region and Customer Area (vs. 2024) Reported Restatement Global EMEA North America Asia-Pacific Latin America Global EMEA North America Asia-Pacific Latin America CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER
Slide 152: Diagnostics Division quarterly sales and CER growth
YTD Sep 2025: Diagnostics Division quarterly sales and CER growth1 Reported Restatement Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER Core Lab Core Lab Core Lab Core Lab3 1,983
Slide 153: YTD Sep 2025: Diagnostics Division regional sales
YTD Sep 2025: Diagnostics Division regional sales Growth across regions, offset by APAC Sales YTD CHFm & % of total sales Total YTD Sales = 10,307 Growth at CER % Growth at CERm 1 +241 769 / EMEA +6 7% North America +7 -471 2,547 / 3,686 / of which US +6 25% 36% +217 +91 Asia-Pacific -15 +104 of whi
Slide 154: Core Lab
Core Lab 2025 vs. 2024 CER growth CHFbn -1% 7.5 +4% 6.0 +6% -5% 4.5 3.0 1.5 0.0 YTD Sep 2023 YTD Sep 2024 YTD Sep 2025 Immunodiagnostics Clinical Chemistry Other CER: Constant exchange rates (avg. full year 2024) 154
Slide 155: Molecular Lab
Molecular Lab 2025 vs. 2024 CER growth CHFbn +4% 2.0 +17% 1.6 - -13% 1.2 -2% -5% 0.8 -1% 0.4 +5% 0% 0.0 YTD Sep 2023 YTD Sep 2024 YTD Sep 2025 Infectious Diseases Blood Screening MD Systems Open Molecular Systems Cervical Cancer Sequencing ML PHCS Other CER: Constant exchange rates (avg. full year 2
Slide 156: Near Patient Care
Near Patient Care 2025 vs. 2024 CER growth CHFbn -4% 2.0 -3% 1.6 -5% -2% 1.2 -1% 0.8 +3% -23% 0.4 0.0 YTD Sep 2023 YTD Sep 2024 YTD Sep 2025 Clinical Chem. & Immunodiagn. Hospital Glucose Coagulation & Urinalysis BGM POC MDx Other CER: Constant exchange rates (avg. full year 2024); BGM: Blood Glucos
Slide 157: Pathology Lab
Pathology Lab 2025 vs. 2024 CER growth CHFbn +13% 1.5 - 1.2 +21% +17% 0.9 +10% 0.6 0.3 0.0 YTD Sep 2023 YTD Sep 2024 YTD Sep 2025 Advanced Staining Primary Staining PL PHCS Other CER: Constant exchange rates (avg. full year 2024); PHCS: Personalised Healthcare Solutions; PL: Pathology Lab 157
Slide 158: Roche Group development pipeline
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 159: CHF/USD
CHF/USD Monthly averages 1.00 0.90 0% 0.80 -9% -6% 0.70 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2024 2025 Year-to-date averages 0.95 3% 0.85 -3% -4% 0.75 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2024 2025 159
Slide 160: CHF/USD
CHF/USD 0.95 YTD Sep 2025 -4% 0.93 0.91 0.89 0.87 0.85 0.83 0.81 0.79 0.77 0.75 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec avg. full year 2024 avg. full year 2025 monthly avg. 2024 monthly avg. 2025 160
Slide 161: CHF/EUR
CHF/EUR Monthly averages 1.00 0.95 -1% -3% -1% 0.90 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2024 2025 Year-to-date averages 1.00 0.98 0.96 0.94 0.92 0% -2% -2% 0.90 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2024 2025 161
Slide 162: CHF/EUR
CHF/EUR 1.00 YTD Sep 2025 -1% 0.99 0.98 0.97 0.96 0.95 0.94 0.93 0.92 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec avg. full year 2024 avg. full year 2025 monthly avg. 2024 monthly avg. 2025 162
Slide 163: Average CHF exchange rates
Average CHF exchange rates YTD Sep YTD Sep YTD Sep 2025 vs. YTD Sep 2024 2025 2024 USD 0.84 0.88 -4% EUR 0.94 0.96 -2% JPY 0.57 0.58 -3% -6% -4% -2% 0% 163
Slide 164: Exchange rate impact on sales growth
Exchange rate impact on sales growth YTD Sep 2025: Negative impact of CNY, USD, JPY and EUR Development of average exchange rates versus prior year period Q1 HY YTD Sep FY CHF / USD 2.9% -2.9% -4.4% CHF / EUR -0.3% -2.1% -1.9% CHF / JPY 0.1% -0.6% -2.6% CHF / CNY 1.7% -3.3% -4.6% Difference in CHF /
Slide 165: Exchange rate impact on sales growth
Exchange rate impact on sales growth YTD Sep 2025: Negative impact of USD, CNY, JPY and EUR Development of average exchange rates versus prior year period Q1 Q2 Q3 Q4 CHF / USD 2.9% -8.5% -7.6% CHF / EUR -0.3% -3.8% -1.7% CHF / JPY 0.1% -1.5% -6.6% CHF / CNY 1.7% -8.2% -7.4% Difference in CHF / CER
Slide 166: Doing now what patients need next
Doing now what patients need next